Brain drug revival

Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

https://www.biopharmadive.com/news/acadia-research-sales-update-nuplazid-daybue-pipeline/751745/


On Wednesday, Acadia also predicted the combined peak sales of Nuplazid and its other commercial medication, Daybue, will fall in the range of $1.5 billion to $2 billion. Approved in 2023, Daybue is used for patients with Rett syndrome, a rare, genetic disorder that impairs brain function and development.

Along with ACP-204, Acadia’s pipeline includes ACP-101, a drug for another rare, genetic, neurological disease called Prader-Willi Syndrome. High-level results from a Phase 3 experiment should arrive sometime between October and December. There’s also ACP-211, for major depression; ACP-711, for essential tremor; and ACP-2591, a “next-generation” approach to addressing Rett syndrome. Each of those three programs are in early-stage testing.